The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Published Online:

Thirteen patients with tardive dyskinesia were treated with either haloperidol or tetrabenazine for 18 weeks. Haloperidol produced a statistically significant reduction in the frequency of oral dyskinesia, though the effect was most striking during the first two weeks; reversible extrapyramidal symptoms appeared to be negatively correlated with oral dyskinesia. Tetrabenazine also produced a significant reduction in the frequency of oral dyskinesia, with almost complete suppression in two patients throughout the study; the correlation between oral dyskinesia and reversible extrapyramidal symptoms was less clear than with haloperidol. No exacerbation of the dyskinesia was observed after administration of the study drugs was discontinued.

Access content

To read the fulltext, please use one of the options below to sign in or purchase access.